FDA Commissioner Scott Gottlieb said the U.S. has a "wacky" system where discounts on drug prices don't flow to patients paying for drugs. Rebates are a favorite target of pharmaceutical companies, who say pharmaceutical benefit managers extract huge discounts but keep them for themselves instead of sharing the savings with patients.